Following the Pet Food Recall of 2007 due to melamine and its analogues being used to adulterate feeds to fake protein content, CVM began a series of studies to evaluate potential future risks. During the 2008 Melamine in Chinese Milk Products/Infant Formula event, CVM attended a joint Chinese-FDA Workshop on Melamine with the FDA Commissioner during November 2008 (details below). CVM also participated with CFSAN in updating the FDA Melamine Risk Assessment.
In November of 2008, CVM sent a representative with a delegation from the FDA Commissioner’s Office to Beijing, China to participate in a workshop and make presentations to the General Administration of Quality Supervision, Inspection and Quarantine of China (AQSIQ). This workshop covered a variety of topics relating to melamine induced renal injury, in animals and humans, including background on the pet food recall event of 2007, a review of melamine related toxicity, updates on current laboratory analytical detection methods for melamine and analogues, risk assessments, and monitoring and compliance programs, and case presentations of infants by Chinese pediatricians. As a result of this workshop, pediatricians and CVM scientists have continued dialogues about recent research findings.
In December of 2008, CVM sent a representative to the WHO Expert Meeting in Ottawa, Canada to review toxicological aspects of melamine and cyanuric acid in collaboration with FAO. CVM participated in the preparation of background documents for this meeting and the final document Toxicological and Health Aspects of Melamine and Cyanuric Acid. As a result of this workshop CVM experts have been very helpful in influencing and providing data to WHO and Codex in efforts to set international residue limits for melamine and related analogues.